Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00841971 · ClinicalTrials.gov registry record · Phase 4

Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients

A Phase 4 study of Mycoses and Fungemia, sponsored by University of Pittsburgh.

Completed
Registry status
Phase 4
Development phase
200
Enrollment target
6
Study locations

NCT00841971 is a Phase 4 study of Mycoses and Fungemia that has completed, run by University of Pittsburgh. The registered enrollment target is 200 participants, below the 318-participant average among 7 other Mycoses trials with a reported enrollment target (37% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00841971, a Phase 4 study of Mycoses and Fungemia, has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
Phase 4
Development phase
200 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this study is to compare the efficacy of anidulafungin versus fluconazole for the prevention of fungal diseases in liver transplant recipients

Interventions

  • DRUG Fluconazole
  • DRUG Anidulafungin

Study Locations (6)

California

  • UCLA Medical Cente - Los Angeles

Florida

  • University of Miami - Miami

Michigan

  • University of Michigan - Ann Arbor

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Washington

  • University of Washington Medical Center - Seattle

Wisconsin

  • University of Wisconsin - Madison - Madison

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2010-02
Est. Completion 2014-05
Phase Phase 4

Sponsor

University of Pittsburgh

1,238 total trials

What the Registry Record Tells You About NCT00841971

The ClinicalTrials.gov registry entry for NCT00841971 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 318-participant average among 7 other Mycoses trials with a reported enrollment target (37% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Mycoses appearing as the primary indexed condition, and to 2 interventions - of which Fluconazole is the first listed.

NCT00841971 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Michigan.

Frequently Asked Questions

What is clinical trial NCT00841971 about?

NCT00841971 is a clinical study titled "Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients". The purpose of this study is to compare the efficacy of anidulafungin versus fluconazole for the prevention of fungal diseases in liver transplant recipients

What is the current status of trial NCT00841971?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2010-02. Estimated completion is 2014-05.

What conditions does trial NCT00841971 study?

This clinical trial studies the following conditions: Mycoses, Fungemia, Central Nervous System Fungal Infections, Lung Diseases, Fungal.

What interventions are being tested in trial NCT00841971?

The interventions under investigation include: Fluconazole (DRUG), Anidulafungin (DRUG).

Who is sponsoring clinical trial NCT00841971?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00841971 being conducted?

This trial has 6 study locations across California, Florida, Michigan, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mycoses

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.